The president at Cala Health discussed the clinical role, evidence base, and future potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.
Kate Rosenbluth, PhD
Advertisement
President and co-founder at Cala Health.
Articles by Kate Rosenbluth, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Improving Recognition and Treatment of Hyperkinetic Movement Disorders: Zoltan Mari, MD
2
Current and Emerging Strategies for Managing Huntington Disease Symptoms: Karen Anderson, MD
3
Disappointing Interim Analysis Forces Sanofi to Discontinue Phase 3 MOBILIZE Trial of Riliprubart
4
FDA Action Update, May 2026: Approvals, Priority Review, and Extension of Review
5